Migration in Europe: an interactive guide in 9 languages produced by 6 European press agencies including AFP

Poverty, hunger, the effects of climate change and armed conflicts, such as the war in Ukraine, mean that the number of migrants trying to reach Europe, continues to rise.

Anglais

Topshots of the Week (28 April - 5 May, 2023)

Selection of some of the most striking photographs taken by AFP photojournalists this past week (28 April - 5 May, 2023).


Plane flies by a statue of the Louvre, while the moon rises, Paris

A plane flies by a statue of the Louvre as the waxing gibbous moon rises in Paris, on May 3, 2023.
© Stefano RELLANDINI / AFP

Topshots of the Week (8-14 April, 2023)

Selection of some of the most striking photographs taken by AFP photojournalists this past week (8-14 April, 2023).


Cotopaxi volcano - Quito, Ecuador

A plume of steam and gas billows from the Cotopaxi volcano as seen from Quito, Ecuador, on April 10, 2023.
© Rodrigo BUENDIA / AFP

02/03/2026 15:15
Volante Technologies named a Leader in Gartner® Magic Quadrant™ for Banking Payment Hub Platforms

Volante Technologies, the global leader in Payments as a Service (PaaS), today announced its recognition as a Leader in the 2026 Gartner® Magic Quadrant™ for Banking Payment Hub Platforms, which evaluates vendors based on Ability to Execute and Completeness of Vision. In Volante’s view, Gartner positioned them as a Leader based on their capacity to support enterprise-scale payment processing in banks and financial institutions across multiple regions, deployment models, and operational environm...

02/17/2026 11:30
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsbe...